MSD to collaborate with Fujifilm Diosynth on new microbial biologics facility

pharmafile | June 7, 2016 | News story | Manufacturing and Production, Research and Development MSD, Merck, fujifilm diosynth 

MSD, known as Merck in the US and Canada, has entered into a collaboration with Fujifilm Diosynth Biotechnologies to invest in and operate a large-scale microbial-biologics facility for supply of active pharmaceutical ingredients to its customers.

The collaboration will involve a $60 million investment by MSD at its Brinny manufacturing plant in Innishannon, in County Cork, Ireland. The site at Brinny has been in operation for more than 30 years and is an integrated site for development, testing and manufacturing of biologics.

The large-scale biologics operations at MSD in Brinny are set to operational in early 2018. Sanat Chattopadhyay, president of the manufacturing division at MSD, says: “MSD is excited to collaborate with Fujifilm Diosynth through expanded capabilities in bulk microbial fermentation and downstream support services. This will allow MSD to use and further develop the skills and competencies of the people at the MSD site in Brinny and build on the site’s long tradition of manufacturing excellence.”

Sean Murray

Related Content

Merck to acquire Caraway Therapeutics for up to $610m

Merck (known as MSD outside of the US and Canada) and Caraway Therapeutics have announced …

FDA approves Merck’s Keytruda for gastric cancer treatment

Merck, known as MSD outside of the US, has announced that the US Food and …

Merck’s Keytruda approved by EC for gastric cancer

Merck (known as MSD outside of the US and Canada) has announced the approval of …

Latest content